Milestone Pharmaceuticals Inc.（简称里程碑制药）宣布启动一项名为Reset-Psvt的登记研究项目。该项目旨在收集关于其核心产品Cardamyst™（Etripamil）鼻喷雾剂在阵发性室上性心动过速（PSVT）患者群体中应用的真实世界临床数据。通过系统性登记患者使用情况，该研究将为药物在实际临床环境中的疗效与安全性提供重要佐证。
Milestone Pharmaceuticals Inc.（简称里程碑制药）宣布启动一项名为Reset-Psvt的登记研究项目。该项目旨在收集关于其核心产品Cardamyst™（Etripamil）鼻喷雾剂在阵发性室上性心动过速（PSVT）患者群体中应用的真实世界临床数据。通过系统性登记患者使用情况，该研究将为药物在实际临床环境中的疗效与安全性提供重要佐证。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.